Susmed

Susmed OCF Margin

The Operating Cash Flow Margin of Susmed (4263.T) as of Oct 29, 2026 is -95.42 %. In the previous year, Operating Cash Flow Margin was -93.41 % — a change of 2.16% (lower).

OCF Margin

-95.42 %

YoY

2.16%

Last updated:

Operating Cash Flow Margin of Susmed is 2026 -95.42 % . Operating Cash Flow Margin of Susmed was 2025 -93.41 % . It decreases by 2.16% lower compared to the previous year.

The Susmed OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2020
-255.07 JPY
Jan 1, 2021
-203.56 JPY
Jan 1, 2022
-52.16 JPY
Jan 1, 2023
18.96 JPY
Jan 1, 2024
-67.36 JPY
Jan 1, 2025
-93.41 JPY
Jan 1, 2026
-95.42 JPY
The Susmed OCF Margin history
YEAROCF MarginYoY
-95.42 %+2.16%
-93.41 %+38.67%
-67.36 %-455.35%
18.96 %-136.34%
-52.16 %-74.38%
-203.56 %-20.19%
-255.07 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Susmed Stock analysis

What does Susmed do? SUSMED, Inc. generates revenue through its DTx Product segment, which develops application software for treating insomnia, breast cancer, and chronic kidney diseases. The DTx Platform segment provides clinical trial systems, machine learning analysis systems, and DTx development support services. The company's primary customers are healthcare providers and pharmaceutical companies seeking digital therapeutics solutions. SUSMED targets the healthcare technology market with its specialized software and support services for disease treatment and clinical research. The DTx Product segment focuses on creating therapeutic applications for specific medical conditions, while the DTx Platform segment offers infrastructure for clinical trials and machine learning analysis. SUSMED's business model relies on selling both its proprietary software products and platform services to healthcare institutions and pharmaceutical firms. The company's revenue streams include software licensing, system subscriptions, and development support fees. SUSMED's products are designed to address chronic conditions like insomnia and breast cancer, with additional focus on chronic kidney diseases. The DTx Platform serves as a comprehensive solution for clinical trial management and machine learning-driven analysis, supporting pharmaceutical companies in their drug development processes. The company's services are tailored to meet the needs of healthcare technology providers and pharmaceutical developers. Susmed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Susmed stock

Operating Cash Flow Margin of Susmed is -95.42 % in 2026.

Operating Cash Flow Margin of Susmed changed from -93.41 % to -95.42 %, representing a 2.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Susmed since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Susmed with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Susmed

All Key Metrics — Susmed